Blastic plasmacytoid dendritic cell neoplasm in children: Diagnostic features and clinical implications

Haematologica

Volumn 95, Issue 11, 2010, Pages 1873-1879

  Jegalian, Armin G ^a   Buxbaum, Nataliya P ^a   Facchetti, Fabio ^b   Raffeld, Mark ^a   Pittaluga, Stefania ^a   Wayne, Alan S ^a   Jaffe, Elaine S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; Blastic plasmacytoid dendritic cell neoplasm; CD4+ CD56+ hematodermic neoplasm; Dendritic cells; Immunophenotyping; Pediatric; S 100; Stem cell transplant

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PREDNISONE; PROTEIN S 100; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADOLESCENT; ARTICLE; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INFANT; LEUKEMIA REMISSION; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SKIN DISEASE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PLASMACYTOMA; RECURRENCE; RETROSPECTIVE STUDIES; S100 PROTEINS; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 78149247393     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.026179     Document Type: Article

References (40)

1. Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99(5):1556-63.
2. Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M, et al. Blastic NKcell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123(5):662-75.
3. Reichard KK, Burks EJ, Foucar MK, Wilson CS, Viswanatha DS, Hozier JC, et al. CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol. 2005; 29(10):1274-83.
4. Herling M, Jones D. CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol. 2007;127(5):687-700.
5. Jegalian AG, Facchetti F, Jaffe ES. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol. 2009;16(6):392-404.
6. Lucio P, Parreira A, Orfao A. CD123hi dendritic cell lymphoma: an unusual case of non-Hodgkin lymphoma. Ann Intern Med. 1999;131(7):549-50.
7. Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97(10):3210-7.
8. Petrella T, Comeau MR, Maynadie M, Couillault G, De Muret A, Maliszewski CR, et al. 'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol. 2002;26(7):852-62.
9. Chaperot L, Perrot I, Jacob MC, Blanchard D, Salaun V, Deneys V, et al. Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol. 2004;34 (2):418-26.
10. Marafioti T, Paterson JC, Ballabio E, Reichard KK, Tedoldi S, Hollowood K, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood. 2008;111(7):3778-92.
11. Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood. 2007;109(4):1720-7.
12. Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity. 2008;29(3):352-61.
13. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5(12):1219-26.
14. Merad M, Manz MG. Dendritic cell homeostasis. Blood 2009;113(15):3418-27.
15. Liu K, Victora GD, Schwickert TA, Guermonprez P, Meredith MM, Yao K, et al. In vivo analysis of dendritic cell development and homeostasis. Science. 2009; 324(5925):392-7.
16. Reimer P, Rudiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637-46.
17. Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010;162(1):74-9.
18. Shaw PH, Cohn SL, Morgan ER, Kovarik P, Haut PR, Kletzel M, et al. Natural killer cell lymphoma: report of two pediatric cases, therapeutic options, and review of the literature. Cancer. 2001;91(4):642-6.
19. Falcao RP, Garcia AB, Marques MG, Simoes BP, Fonseca BA, Rodrigues ML, et al. Blastic CD4 NK cell leukemia/lymphoma: a distinct clinical entity. Leuk Res. 2002;26 (9):803-7.
20. Anargyrou K, Paterakis G, Boutsis D, Politou M, Papadhimitriou SI, Siakandaris M, et al. An unusual case of CD4+ CD7+ CD56+ acute leukemia with overlapping features of type 2 dendritic cell (DC2) and myeloid/NK cell precursor acute leukemia. Eur J Haematol. 2003;71(4):294-8.
21. Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Suefuji H, Suzumiya J, et al. Non-B, non-T neoplasms with lymphoblast morphology: further clarification and classification. Am J Surg Pathol. 2003;27 (10):1366-74.
22. Kim Y, Kang MS, Kim CW, Sung R, Ko YH. CD4+CD56+ lineage negative hematopoietic neoplasm: so called blastic NK cell lymphoma. J Korean Med Sci. 2005;20(2):319-24.
23. Rossi JG, Felice MS, Bernasconi AR, Ribas AE, Gallego MS, Somardzic AE, et al. Acute leukemia of dendritic cell lineage in childhood: incidence, biological characteristics and outcome. Leuk Lymphoma. 2006; 47(4):715-25.
24. Ruggiero A, Maurizi P, Larocca LM, Arlotta A, Riccardi R. Childhood CD4+/CD56+ hematodermic neoplasm: case report and review of the literature. Haematologica. 2006;91(12 Suppl):ECR48.
25. Pilichowska ME, Fleming MD, Pinkus JL, Pinkus GS. CD4+/CD56+ hematodermic neoplasm (blastic natural killer cell lymphoma): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. Am J Clin Pathol. 2007;128(3):445-53.
26. Eguaras AV, Lo RW, Veloso JD, Tan VG, Enriquez ML, Del Rosario ML. CD4+/CD56+ hematodermic neoplasm: blastic NK cell lymphoma in a 6-year-old child: report of a case and review of literature. J Pediatr Hematol Oncol. 2007;29(11): 766-9.
27. Hu SC, Tsai KB, Chen GS, Chen PH. Infantile CD4+/CD56+ hematodermic neoplasm. Haematologica 2007;92(9):e91-3.
28. Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, et al. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009:145:624-36.
29. Hama A, Kudo K, Itzel BV, Muramatsu H, Nishio N, Yoshida N, et al. Plasmacytoid dendritic cell leukemia in children. J Pediatr Hematol Oncol. 2009;31(5):339-43.
30. Reineks EZ, Osei ES, Rosenberg A, Auletta J, Meyerson HJ. CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti-CD22 antibodies to peripheral blood dendritic cells. Cytometry B Clin Cytom. 2009;76B(4):237-48.
31. Tsagarakis NJ, Kentrou NA, Papadimitriou KA, Pagoni M, Kokkini G, Papadaki H, et al. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res. 2010;34(4):438-46.
32. Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood. 2003;101(12):5007-9.
33. Petrella T, Meijer CJ, Dalac S, Willemze R, Maynadie M, Machet L, et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol. 2004;122(2):307-13.
34. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000;165(11):6037-46.
35. Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, et al. Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood. 2005;105(3):1256-64.
36. McCarthy KP, Sloane JP, Kabarowski JH, Matutes E, Wiedemann LM. A simplified method of detection of clonal rearrangements of the T-cell receptor-gamma chain gene. Diagn Mol Pathol. 1992;1(3):173-9.
37. Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010;34(3):405-17.
38. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H, editors. Lyon, France: International Agency for Research on Cancer; 2008.
39. Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010;34(1):75-87.
40. Bekkenk MW, Jansen PM, Meijer CJ, Willemze R. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004;15(7): 1097-108.